Effective October 31, 2025, MABPHARM-B (02181) announced the following changes: Dr. Qian Weizhu, an executive director, has been appointed as a member of the company's nomination committee. Mr. Tao Jing, also an executive director, has stepped down from his role on the nomination committee. Additionally, Dr. Zhang Yanyun, currently serving as an independent non-executive director, chair of the remuneration committee, and member of the nomination committee, has been designated as the lead independent non-executive director.